Portland, OR, United States of America

James Matthew Meinig

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 5.5

ph-index = 3

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: James Matthew Meinig: Innovator in Pharmaceutical Compounds

Introduction

James Matthew Meinig is a prominent inventor based in Portland, OR (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating neurodegenerative diseases. With a total of 6 patents to his name, Meinig's work is recognized for its potential impact on medical science.

Latest Patents

Among his latest patents, Meinig has developed amide compounds and pharmaceutical compositions that utilize these compounds. These amide compounds are disclosed alongside methods for treating neurodegenerative diseases, which involve administering the compounds or pharmaceutical compositions to a subject. Additionally, he has worked on ester derivatives of sobetirome, which are designed to enhance central nervous system (CNS) distribution.

Career Highlights

James Matthew Meinig is affiliated with Oregon Health & Science University, where he continues to advance his research and innovation in pharmaceutical sciences. His work is characterized by a commitment to improving treatment options for patients suffering from complex neurological conditions.

Collaborations

Meinig has collaborated with notable colleagues, including Thomas S. Scanlan and Tapasree Banerji, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

James Matthew Meinig's contributions to pharmaceutical inventions highlight his dedication to addressing critical health challenges. His innovative work continues to pave the way for advancements in the treatment of neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…